Victoria Williams Pharm.D., Rupal Parbhoo Pharm.D., Bruce Doepker Pharm.D., Claire Murphy Pharm.D., Lynn Wardlow Pharm.D., Kevin Kissling Pharm.D., Megan Bond Pharm.D., Kelly Bartsch Pharm.D., Sree Satyapriya M.D., Markisha Wilder M.S., Jessica Greco M.D., Anthony Gerlach Pharm.D.
{"title":"在一个学术医疗中心实施胱抑素c引导估计肾小球滤过率的用药剂量","authors":"Victoria Williams Pharm.D., Rupal Parbhoo Pharm.D., Bruce Doepker Pharm.D., Claire Murphy Pharm.D., Lynn Wardlow Pharm.D., Kevin Kissling Pharm.D., Megan Bond Pharm.D., Kelly Bartsch Pharm.D., Sree Satyapriya M.D., Markisha Wilder M.S., Jessica Greco M.D., Anthony Gerlach Pharm.D.","doi":"10.1002/jac5.70035","DOIUrl":null,"url":null,"abstract":"<p>Accurate kidney function assessment is essential for medication dosing, although traditional methods such as urine output and serum creatinine are limited, especially in patients with acute kidney injury. Cystatin C was made available as an alternative marker at our institution, prompting the formation of a multidisciplinary task force to guide its use and resolve discrepancies in clinical practice using a Plan-Do-Study-Act framework. Plan-Do-Study-Act is a validated approach to developing and evaluating interventions to ensure that changes to a process result in the desired improvement. The task force developed pharmacist-focused education, creating guidance documents and asynchronous training with competency assessments. An audit revealed that cystatin C was primarily used in intensive care units for dosing antibiotics like cefepime and vancomycin. In response, updates to clinical decision support systems in electronic medical records were made. A progress note template was designed and implemented to communicate cystatin C assessments and dosing changes based on this kidney filtration marker. Ongoing quality improvement efforts are focusing on broadening education, refining documentation, and researching optimal cystatin C use.</p>","PeriodicalId":73966,"journal":{"name":"Journal of the American College of Clinical Pharmacy : JACCP","volume":"8 5","pages":"376-384"},"PeriodicalIF":1.3000,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jac5.70035","citationCount":"0","resultStr":"{\"title\":\"Implementing use of cystatin C-guided estimated glomerular filtration rate for medication dosing at an Academic Medical Center\",\"authors\":\"Victoria Williams Pharm.D., Rupal Parbhoo Pharm.D., Bruce Doepker Pharm.D., Claire Murphy Pharm.D., Lynn Wardlow Pharm.D., Kevin Kissling Pharm.D., Megan Bond Pharm.D., Kelly Bartsch Pharm.D., Sree Satyapriya M.D., Markisha Wilder M.S., Jessica Greco M.D., Anthony Gerlach Pharm.D.\",\"doi\":\"10.1002/jac5.70035\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Accurate kidney function assessment is essential for medication dosing, although traditional methods such as urine output and serum creatinine are limited, especially in patients with acute kidney injury. Cystatin C was made available as an alternative marker at our institution, prompting the formation of a multidisciplinary task force to guide its use and resolve discrepancies in clinical practice using a Plan-Do-Study-Act framework. Plan-Do-Study-Act is a validated approach to developing and evaluating interventions to ensure that changes to a process result in the desired improvement. The task force developed pharmacist-focused education, creating guidance documents and asynchronous training with competency assessments. An audit revealed that cystatin C was primarily used in intensive care units for dosing antibiotics like cefepime and vancomycin. In response, updates to clinical decision support systems in electronic medical records were made. A progress note template was designed and implemented to communicate cystatin C assessments and dosing changes based on this kidney filtration marker. Ongoing quality improvement efforts are focusing on broadening education, refining documentation, and researching optimal cystatin C use.</p>\",\"PeriodicalId\":73966,\"journal\":{\"name\":\"Journal of the American College of Clinical Pharmacy : JACCP\",\"volume\":\"8 5\",\"pages\":\"376-384\"},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2025-04-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jac5.70035\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of the American College of Clinical Pharmacy : JACCP\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jac5.70035\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the American College of Clinical Pharmacy : JACCP","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jac5.70035","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Implementing use of cystatin C-guided estimated glomerular filtration rate for medication dosing at an Academic Medical Center
Accurate kidney function assessment is essential for medication dosing, although traditional methods such as urine output and serum creatinine are limited, especially in patients with acute kidney injury. Cystatin C was made available as an alternative marker at our institution, prompting the formation of a multidisciplinary task force to guide its use and resolve discrepancies in clinical practice using a Plan-Do-Study-Act framework. Plan-Do-Study-Act is a validated approach to developing and evaluating interventions to ensure that changes to a process result in the desired improvement. The task force developed pharmacist-focused education, creating guidance documents and asynchronous training with competency assessments. An audit revealed that cystatin C was primarily used in intensive care units for dosing antibiotics like cefepime and vancomycin. In response, updates to clinical decision support systems in electronic medical records were made. A progress note template was designed and implemented to communicate cystatin C assessments and dosing changes based on this kidney filtration marker. Ongoing quality improvement efforts are focusing on broadening education, refining documentation, and researching optimal cystatin C use.